Quantcast
Channel: WN.com - Articles related to AstraZeneca in Deal for Pearl Therapeutics Worth Up to $1.15 Billion
Browsing all 59 articles
Browse latest View live

AstraZeneca buys lung drug firm Pearl for up to $1.15 billion

LONDON (Reuters) - AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15...

View Article



AstraZeneca buys company that develops products for respiratory disease

LONDON — British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary...

View Article

UPDATE 1-AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 bln

* $560 mln upfront payment, further payouts on drug success * Purchase takes AstraZeneca into emerging LABA/LAMA market * Deal expected to close in Q3, 2013 forecasts unaffected By Ben Hirschler...

View Article

AstraZeneca to Pay Up to $1.15 Billion for Pearl

AstraZeneca Plc (AZN) agreed to buy Pearl Therapeutics, a closely held U.S. maker of therapies for respiratory disease, for as much as...

View Article

>AstraZeneca in $560 m deal for respiratory firm

LONDON (AP) — British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company...

View Article


AstraZeneca in $560 m deal for respiratory firm

LONDON — British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic...

View Article

Elan board rejects higher Royalty Pharma bid

Elan Corp’s board of directors unanimously rejected a higher takeover offer from Royalty Pharma, an investor in royalty streams from pharmaceuticals, and has instructed advisers at Citigroup Inc to...

View Article

Weighing Alternatives to a Telecom Deal

> Sprint Nextel’s path to recovery once seemed clear, involving a sale to SoftBank of Japan and a deal to buy full control of the wireless network operator Clearwire. But that plan has been...

View Article


AstraZeneca to buy Pearl Therapeutics for up to $1.1B

Pearl Therapeutics, led by CEO Chuck Bramlage, has agreed to be acquired for up to $1.15B by AstraZeneca. Senior Technology Reporter- Silicon Valley Business Journal | | AstraZeneca said on Monday that...

View Article


AstraZeneca set to buy US respiratory drug firm

Related articles AstraZeneca takes $140m hit as it pulls plug on rheumatoid arthritis pill AstraZeneca to build cardiovascular drug unit AstraZeneca sales hit by generic drug competition AstraZeneca...

View Article

AstraZeneca buys US lung drug firm Pearl Therapeutics

AstraZeneca, the UK's second largest drugs company, has announced it is buying California-based Pearl Therapeutics in a deal worth up to $1.15bn (£742m). Privately-owned Pearl specialises in drugs used...

View Article

AstraZeneca (AZN) to Acquire Pearl Therapeutics in $1.15B Deal

Tweet Send to a Friend Get Alerts AZN Hot Sheet Price: $51.45 --0% Overall Analyst Rating: NEUTRAL ( Up) Trade AZN Now! AstraZeneca (NYSE: AZN) has entered into a definitive agreement to acquire Pearl...

View Article

AstraZeneca to buy US respiratory drug specialist Pearl

Deal worth up to $1.15bn secures AstraZeneca a position in emerging market for new class of lung treatments Pascal Soriot, the AstraZeneca chief executive. Photograph: Reuters AstraZeneca is to buy the...

View Article


AstraZeneca deals run goes on as it buys rival for $1.1bn

The company is hoping to restore its fortunes after a string of late-stage research failures. It has also seen a number of big sellers fall out of patent, and stalwarts Nexium and Crestor are set to...

View Article

AstraZeneca Buys Pearl for Up to $1.15 Billion

AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion, as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via...

View Article


AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio...

(Source: AstraZeneca plc) AstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused...

View Article

AstraZeneca buys US lung drug firm Pearl for up to $1.15 billion

AstraZeneca is to buy US respiratory drug specialist Pearl Therapeutics for up to $1.15 billion (€870 million) as Britain’s second biggest drugmaker steps up a drive to rebuild its product pipeline via...

View Article


Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion

Tweet Send to a Friend Redwood City, CA, June 10, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that it has entered into a definitive merger agreement under which the Company will be...

View Article

AstraZeneca to buy Pearl Therapeutics for $1.15 billion

John Sailors AstraZeneca Plc has agreed to buy the respiratory drug maker Pearl Therapeutics for up to $1.15 billion. AstraZeneca will pay an initial $560 million for Redwood City-based Pearl...

View Article

AstraZeneca in $1.15 Billion Deal for Pearl Therapeutics

> LONDON – The European drug maker AstraZeneca agreed on Monday to buy the American respiratory drug manufacturer Pearl Therapeutics for up to $1.15 billion Under the terms of the deal, AstraZeneca...

View Article
Browsing all 59 articles
Browse latest View live




Latest Images